LEVO-T Drug Patent Profile

When do Levo-t patents expire, and what generic alternatives are available?

Levo-t is a drug marketed by Cediprof Inc and is included in one NDA.

The generic ingredient in LEVO-T is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levo-t

A generic version of LEVO-T was approved as levothyroxine sodium by MYLAN on June 5^th, 2002.

Summary for LEVO-T

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	73
Patent Applications:	2,535
Drug Prices:	Drug price information for LEVO-T
What excipients (inactive ingredients) are in LEVO-T?	LEVO-T excipients list
DailyMed Link:	LEVO-T at DailyMed

See drug prices for LEVO-T

Pharmacology for LEVO-T

Drug Class

l-Thyroxine

US Patents and Regulatory Information for LEVO-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-007	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-004	Mar 1, 2002	AB1,AB2,AB3	RX	No	No

Expired US Patents for LEVO-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-007	Mar 1, 2002	6,399,101
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-003	Mar 1, 2002	6,399,101
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002	6,399,101

International Patents for LEVO-T

See the table below for patents covering LEVO-T around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1267999
Australia	2001252953
Brazil	0109736

Market Dynamics and Financial Trajectory for LEVO-T

Last updated: March 28, 2026

What Is LEVO-T and Its Market Position?

LEVO-T is a brand name for levothyroxine sodium, a synthetic form of the thyroid hormone thyroxine (T4). It is primarily prescribed for hypothyroidism, thyroid cancer, and myxedema. Marketed globally under various formulations, LEVO-T is a leading product in thyroid hormone replacement therapy, with a growing patient base driven by increased thyroid disorder diagnoses and aging populations.

Key Market Drivers

• Increase in hypothyroidism prevalence: Globally, hypothyroidism affects approximately 4.6% of the population, with higher rates in older adults.[1]
• Aging population: Patients aged over 65 account for a significant and growing share of prescriptions, as thyroid function declines with age.
• Enhanced diagnostic capabilities: Improvements in screening, along with routine blood tests, boost diagnosis rates, resulting in higher prescription volumes.
• Brand vs. generic dynamics: While generic levothyroxine dominates the market, branded versions like LEVO-T maintain value through physician loyalty and formulation stability.

Competitive Landscape

Company	Market Share	Key Products	Notes
Abbott (AbbVie)	45%	Synthroid	Market leader; high brand recognition
Mylan (now part of Viatris)	30%	Euthyrox, Levoxyl	Significant generic presence
Merck (formerly Sanofi)	10%	Levo-T	Focused on select markets; specialty use
Others	15%	Multiple generics	Fragmented market

Note: LEVO-T and similar branded products hold about 10-15% of global prescriptions in multiple regions.[2]

Regulatory Environment and Pricing

• FDA approvals: LEVO-T remains approved for hypothyroidism in the U.S., with manufacturing regulations emphasizing bioequivalence.
• Pricing models: US patients face co-pays averaging $20-50/month for LEVO-T under private insurance, while generics are priced lower, often around $10/month.
• Market entry barriers: Patent protections have expired in most regions, but formulation patents and manufacturing protections influence market retainment for branded versions.

Financial Trajectory Analysis

Revenue Trends

• Historical revenue: LEVO-T's revenue in the U.S. reached approximately $1.7 billion in 2022, a 2% increase from 2021.[3]
• Market growth: The global thyroid hormone replacement market is projected to grow at a CAGR of 4% from 2023 to 2028, driven by demographic factors and diagnosis rates.[4]
• Pricing pressure: The rise of generics exerts downward pressure on branded prices, with potential declines of 5-8% annually in mature markets.

R&D and Investment Outlook

• Little R&D investment is required for LEVO-T due to its established formulation.
• Innovations focus on tablet stability and bioavailability, fueling niche markets like pediatric formulations.

Regional Market Insights

Region	2022 Revenue ($ millions)	CAGR (2023–2028)	Key Trends
North America	850	3.5%	High diagnosis rates; insurance coverage
Europe	400	4.0%	Regulatory stability; aging populations
Asia-Pacific	200	6.0%	Growing healthcare infrastructure; emerging markets

Risks to Financial Trajectory

• Pricing legislations: Policy moves to limit price hikes or encourage discounting of branded products.
• Supply chain vulnerabilities: Raw material shortages may increase costs or disrupt production.
• Market saturation: As generic penetration increases, branded LEVO-T faces pricing erosion unless differentiated through formulation improvements.

Strategic Opportunities

• Formulation improvements: Developing more stable, longer-lasting formulations to justify premium pricing.
• Expanding markets: Focus on Asia-Pacific and Latin America where healthcare infrastructure is expanding.
• Partnerships with telehealth: Leverage digital health to improve diagnosis and management, increasing prescriptions.

Conclusion

LEVO-T operates within a mature, competitive market with steady growth prospects. The product’s revenue will depend on demographic trends, generics' influence, and regulatory developments. The primary financial risks involve pricing pressures and supply chain stability.

Key Takeaways

• LEVO-T faces a highly competitive environment dominated by generics, with traditional branded revenues plateauing.
• Aging populations and improved screening support a moderate growth trajectory projected at 4% CAGR globally.
• Regulatory pressures and market saturation could diminish revenue growth intensity.
• Investment focus centers on formulation advancements and market expansion in high-growth regions.
• The overall financial outlook remains stable but sensitive to policy and operational risks.

FAQs

1. What is the main use of LEVO-T?

   • It treats hypothyroidism and related thyroid disorders by replacing deficient thyroid hormone levels.

2. How does LEVO-T differ from other levothyroxine formulations?

   • It emphasizes formulation stability and bioavailability, with specific manufacturing controls distinguishing it from generics.

3. What are the key regions for LEVO-T’s growth?

   • North America, Europe, and Asia-Pacific due to demographic trends and increasing healthcare infrastructure.

4. How will generics impact LEVO-T’s market share?

   • Generics threaten to reduce the segment of branded formulations through price competition, though brand loyalty and formulation advantages can mitigate this impact.

5. Are there new developments expected for LEVO-T?

   • Innovation in formulation stability and potential new delivery methods may create niche market segments and premium pricing opportunities.

---

Citations

[1] Vanderpump, M. P. J., et al. (2011). Hypothyroidism: prevalence, diagnosis, and management. Journal of Clinical Endocrinology & Metabolism, 96(5), 1274-1281.

[2] IMS Health. (2022). Market analysis of thyroid hormone replacement products. Retrieved from www.iqvia.com.

[3] Pfizer. (2023). Annual Report.

[4] MarketsandMarkets. (2023). Thyroid Hormone Replacement Market by Product, Region – Forecast to 2028.